Jiyeong Lee1, Sora Mun2, Doojin Kim1, You-Rim Lee2, Dong-Hyuk Sheen3, Chunhwa Ihm4, Seung Hoon Lee5, Hee-Gyoo Kang1,2. 1. Department of Biomedical Laboratory Science, College of Health Sciences, Eulji University, Seongnam, 13135, Korea. 2. Department of Senior Healthcare, BK21 Plus Program, Graduate School, Eulji University, Seongnam, 13135, Korea. 3. Division of Rheumatology, Department of Medicine, Eulji University School of Medicine, Daejeon, 35233, Korea. 4. Department of Laboratory Medicine, Eulji University Hospital, Daejeon, 35233, Korea. 5. Department of Neurosurgery, Eulji University School of Medicine, Daejeon, 35233, Korea.
Abstract
PURPOSE: Rheumatoid arthritis (RA) is an autoimmune disease in which autoantibodies attack the synovial membrane, causing joint inflammation. Blood tests would offer a powerful, minimally invasive method for early diagnosis of RA. However, no reliable biomarkers for RA are presently available. The aim is to develop biomarkers for RA by multiple reaction monitoring (MRM)-based quantification of candidate biomarkers. EXPERIMENTAL DESIGN: Proteomics approaches are commonly used to identify and verify disease biomarkers. For discovery of biomarkers for RA, SWATH acquisition is performed and selected candidate biomarkers are validated by MRM. Target serum proteins are compared between patients with RA and healthy controls divided into three groups based on rheumatoid factor level. RESULTS: A total of 45 differentially expressed proteins are identified, as determined by SWATH acquisition. Of these, 13 proteins are selected as novel candidate biomarkers. A total of five proteins (transthyretin, gelsolin, angiotensinogen, lipopolysaccharide-binding protein, and protein S100-A9) are shown to have the potential to distinguish patients with RA from healthy controls. CONCLUSIONS AND CLINICAL RELEVANCE: These five proteins may improve the efficiency of diagnosis of RA. MRM can be used to easily diagnose RA by detecting five proteins simultaneously in a single sample with high sensitivity.
PURPOSE:Rheumatoid arthritis (RA) is an autoimmune disease in which autoantibodies attack the synovial membrane, causing joint inflammation. Blood tests would offer a powerful, minimally invasive method for early diagnosis of RA. However, no reliable biomarkers for RA are presently available. The aim is to develop biomarkers for RA by multiple reaction monitoring (MRM)-based quantification of candidate biomarkers. EXPERIMENTAL DESIGN: Proteomics approaches are commonly used to identify and verify disease biomarkers. For discovery of biomarkers for RA, SWATH acquisition is performed and selected candidate biomarkers are validated by MRM. Target serum proteins are compared between patients with RA and healthy controls divided into three groups based on rheumatoid factor level. RESULTS: A total of 45 differentially expressed proteins are identified, as determined by SWATH acquisition. Of these, 13 proteins are selected as novel candidate biomarkers. A total of five proteins (transthyretin, gelsolin, angiotensinogen, lipopolysaccharide-binding protein, and protein S100-A9) are shown to have the potential to distinguish patients with RA from healthy controls. CONCLUSIONS AND CLINICAL RELEVANCE: These five proteins may improve the efficiency of diagnosis of RA. MRM can be used to easily diagnose RA by detecting five proteins simultaneously in a single sample with high sensitivity.
Authors: Sarah A Rabah; Indra L Gowan; Maurice Pagnin; Narin Osman; Samantha J Richardson Journal: Front Endocrinol (Lausanne) Date: 2019-08-08 Impact factor: 5.555
Authors: Jessica Feldt; Martin Schicht; Jessica Welss; Kolja Gelse; Stefan Sesselmann; Michael Tsokos; Eileen Socher; Fabian Garreis; Thomas Müller; Friedrich Paulsen Journal: Biomedicines Date: 2022-03-21